MARCHETTI, Antonio
 Distribuzione geografica
Continente #
NA - Nord America 6.781
AS - Asia 4.758
EU - Europa 4.706
SA - Sud America 591
AF - Africa 72
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 10
Totale 16.931
Nazione #
US - Stati Uniti d'America 6.643
SG - Singapore 2.071
CN - Cina 1.300
UA - Ucraina 703
IE - Irlanda 654
IT - Italia 648
RU - Federazione Russa 534
GB - Regno Unito 500
BR - Brasile 486
SE - Svezia 482
DE - Germania 415
TR - Turchia 411
VN - Vietnam 371
FR - Francia 340
FI - Finlandia 207
IN - India 198
HK - Hong Kong 105
CA - Canada 75
MX - Messico 49
PL - Polonia 45
AR - Argentina 43
KR - Corea 39
BD - Bangladesh 36
IQ - Iraq 36
CZ - Repubblica Ceca 32
NL - Olanda 30
JP - Giappone 28
BE - Belgio 26
ES - Italia 22
PK - Pakistan 21
ID - Indonesia 20
TW - Taiwan 19
ZA - Sudafrica 19
AT - Austria 18
EC - Ecuador 16
IL - Israele 13
MY - Malesia 13
SA - Arabia Saudita 13
MA - Marocco 12
AE - Emirati Arabi Uniti 11
IR - Iran 11
KE - Kenya 11
VE - Venezuela 11
EU - Europa 10
LT - Lituania 10
CL - Cile 9
CO - Colombia 9
AU - Australia 8
PY - Paraguay 8
LB - Libano 6
ET - Etiopia 5
GR - Grecia 5
MK - Macedonia 5
NO - Norvegia 5
NZ - Nuova Zelanda 5
PH - Filippine 5
TN - Tunisia 5
BA - Bosnia-Erzegovina 4
DZ - Algeria 4
EG - Egitto 4
GE - Georgia 4
JO - Giordania 4
UY - Uruguay 4
AZ - Azerbaigian 3
BG - Bulgaria 3
CH - Svizzera 3
NG - Nigeria 3
NP - Nepal 3
PE - Perù 3
RO - Romania 3
SN - Senegal 3
UG - Uganda 3
UZ - Uzbekistan 3
BO - Bolivia 2
CR - Costa Rica 2
DK - Danimarca 2
GD - Grenada 2
JM - Giamaica 2
MN - Mongolia 2
NI - Nicaragua 2
RS - Serbia 2
TH - Thailandia 2
AL - Albania 1
AO - Angola 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
EE - Estonia 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
Totale 16.922
Città #
Singapore 1.558
Jacksonville 843
Chandler 823
San Jose 708
Dublin 645
Ashburn 467
Beijing 329
Princeton 323
Dallas 301
Southend 288
Izmir 239
Nanjing 239
Los Angeles 168
Santa Clara 163
Munich 153
Wilmington 137
Cambridge 132
Dearborn 120
Ho Chi Minh City 114
Tongling 114
Altamura 108
New York 104
The Dalles 104
Hong Kong 95
Ann Arbor 90
Boardman 89
Hanoi 74
Buffalo 71
Nanchang 71
Chieti 69
Helsinki 63
Pescara 59
Shenyang 55
Moscow 51
São Paulo 47
Council Bluffs 46
Redondo Beach 44
Hebei 39
Tianjin 39
Warsaw 37
Seoul 36
Rome 35
Woodbridge 35
Kunming 31
Milan 31
Brooklyn 29
Hangzhou 29
Orem 29
Denver 26
Chennai 25
Grevenbroich 25
Washington 25
Chicago 24
Atlanta 23
Norwalk 22
Rio de Janeiro 22
Stockholm 22
Tokyo 22
Augusta 21
Brussels 21
London 21
Frankfurt am Main 20
Jiaxing 20
Mexico City 20
Montreal 20
San Mateo 20
Boston 19
Toronto 19
Baghdad 18
Collecorvino 18
Da Nang 18
Houston 18
Poplar 18
Brno 17
Hefei 17
Nuremberg 17
Belo Horizonte 16
Orange 16
Phoenix 15
Johannesburg 14
Taichung 14
Changsha 13
Guangzhou 13
Latina 13
Turku 13
Haiphong 12
New Delhi 12
San Francisco 12
Vienna 12
Hyderabad 11
Jinan 11
Ningbo 11
Seattle 11
Biên Hòa 10
Fairfield 10
Falls Church 10
Manchester 10
Zhengzhou 10
Campinas 9
Dong Ket 9
Totale 10.339
Nome #
Developing a Decision-making Model Based on an Interdisciplinary Oncological Care Group for the Management of Colorectal Cancer 271
Assessing EGFR mutations. 242
ALK protein analysis by IHC staining after recent regulatory changes: A comparison of two widely used approaches, revision of the literature, and a new testing algorithm 212
A unique microRNA signature associated with plaque instability in humans. 200
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays 182
A multidisciplinary group for prostate cancer management: A single institution experience 181
ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: Results of the first italian external quality assurance scheme 179
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment 177
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. 172
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. 165
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors 160
A unique microRNA signature associated with ischemic stroke in humans 152
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 151
Analysis of DNA Glycosylases MUTYH and OGG1 and Their Correlation with EGFR Signalling in Normal and Nodular Thyroid Tissues 151
ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm 148
AKT1(E17K) in human solid tumours 144
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. 143
Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. 141
HIGH-RISK HUMAN PAPILLOMA VIRUS INFECTION, TUMOR PATHOPHENOTYPES AND BRCA1/2 AND P53 STATUS IN JUVENILE BREAST CANCER PATIENTS. 140
Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle 140
Evaluation of DNA Base Excision Repair and ErbB signaling in euthyroid goiters 140
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. 136
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. 136
ATP-binding cassette transporter A1 (ABCA1) overexpression in hypercholesterolemic plaques: a potential molecular explanation 135
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. 134
KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. 134
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. 133
Overexpression of ABCA1 in human plaques exposed to hypercholesterolemia: the role of microRNA modulation 132
POLE exonuclease domain mutations in endometrial carcinoma: a case report 131
Primary pleuro-pulmonary synovial sarcoma: a single-center 13-year experience 131
Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. 130
Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. 129
Mutational profile of GNAQQ209 in human tumors. 129
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 129
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. 128
2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up 128
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 127
2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer 125
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 125
Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31. 124
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 124
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation 123
Survivin gene expression in early-stage non-small cell lung cancer. 122
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. 121
Association between cigarette smoking and FHIT gene alterations in lung cancer. 121
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. 121
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project 121
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. 120
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 119
Correspondence - In Reply - Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting 118
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. 118
Hypertension is a determinant of ABCA1 expression in atherosclerotic plaques from hypercholesterolemic patients 118
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. 118
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments 117
microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer. 116
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. 115
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 115
mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. 114
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. 114
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. 114
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 114
Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non–Small-cell Lung Cancer: Clinical and Budget Effect 114
Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up 113
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. 113
Lung tumours from non-smoking subjects: A p53-related genetic instability in a subset of cases. 112
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 112
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. 112
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 112
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort 112
Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe 112
Telomerase activity as a prognostic indicator in Stage I Non- Small Cell Lung Cancer -Gruppo Italiano di Patologia Molecolare II Riunione Scientifica. Pisa 20-22 Giugno99 111
p53 alterations in non-small cell lung cancer correlate with metastatic involvement of hilar and mediastinal lymph nodes 111
The chromosomal location of the mouse mammary tumor gene Int6 and related pseudogenes in the mouse genome. 111
mdm2 gene alterations and mdm2 protein expression in breast carcinomas 110
Enriched SSCP: a highly sensitive method for the detection of unknown mutations. Application to the molecular diagnosis of lung cancer in sputum samples. 109
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies 108
Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations 108
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 107
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. 106
2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease 106
Host genetic background effect on the frequency of mouse mammary tumor virus-induced rearrangements of the int-1 and int-2 loci in mouse mammary tumors. 105
Hypertension modulates miR-145 expression in human atherosclerotic plaques 105
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: Results from the ETOP Lungscape Project 105
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project 104
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. 103
Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. 102
The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas. 102
A percutaneous large-needle aspiration biopsy technique for histologic examination of the testis in infertile patients. 102
Nucleotide and deduced amino acid sequences of tumor gene INT6. 100
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. 99
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. 99
Bronchioloalveolar carcinoma: K-ras mutations are constant events in the mucinous subtype 98
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy 97
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients 97
Genetic analysis of lung tumors of non-smoking subject: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus 94
Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. 94
K-ras mutations and cetuximab in colorectal cancer. 93
Real-world data on NGS diagnostics: A survey from the Italian Society of Pathology (SIAPeC) NGS Network 93
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. 90
Predictive markers in lung cancer: A few hints for the practicing pathologist 90
Totale 12.621
Categoria #
all - tutte 66.023
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.023


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021183 0 0 0 0 0 0 0 0 0 130 9 44
2021/2022806 26 14 10 133 53 34 24 55 64 40 107 246
2022/20232.275 221 307 106 268 229 445 138 145 289 15 64 48
2023/20241.013 97 27 63 28 67 294 208 42 11 34 6 136
2024/20253.159 158 598 499 72 74 125 164 161 326 143 326 513
2025/20265.128 452 314 544 684 585 386 803 397 593 370 0 0
Totale 17.264